| Literature DB >> 29866105 |
Zhe Xie1, Yuantao Li1, Lu Long1, Hua Liang2, Weiping Cai3, Tao Shen4.
Abstract
BACKGROUND: Female gender and favorable IFNL3 genotypes are the primary independent predictors of spontaneous clearance of HCV infection. However, chronic hepatitis C infection occurs in numerous women carrying favorable IFNL3 genotypes, indicating that other host and/or virological factors contribute to the prognosis of infection.Entities:
Keywords: HCV; IFNL3; Polymorphism; RORC; Spontaneous clearance
Mesh:
Substances:
Year: 2018 PMID: 29866105 PMCID: PMC5987631 DOI: 10.1186/s12879-018-3153-2
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Flow diagram of study cohort selection. From a total of 1252 residents of Wangying Village, Shangcai County, 190 anti-HCV-positive female Chinese Han individuals were initially recruited to the study after screening. Of these 190 subjects, 53 HIV-positive women with chronic HCV infections were excluded. The remaining 137 females constituted the primary cohort, which consisted of “Chronic” (HIV- HCV carriers, n = 64) and “Resolved” (total n = 73: HIV+ HCV resolvers, n = 28, and HIV- HCV resolvers, n = 45) groups. An IFNL3 favorable sub-cohort was also constructed by exclusion of women with unfavorable IFNL3 genotypes (rs12979860 TC/TT, rs80999917 TG/TT, and rs12980275AG/GG; “Chronic”, n = 54, and “Resolved”, n = 67)
Characteristics of individuals in the primary cohort
| Characteristic | Chronic HCV ( | Resolved HCV (n = 73) | |
|---|---|---|---|
| HIVneg ( | HIVpos ( | ||
| Age (years)a | 50 (47–59) | 59 (49–67) | 54 (47–64) |
| BMIa | 23.5 (21.1–26.1) | 23.2 (21.3–26.3) | 22.1 (20.5–24.5) |
| Anti-HCV | Positive | Positive | Positive |
| Anti-HIV | Negative | Negative | Positive |
| HCV RNA (log10 IU/mL)a | 6.17 (5.82–6.54) | Negative | Negative |
| HCV genotype | |||
| 1b (n,%)b | 39 (60.9%) | – | – |
| 2a (n,%)b | 25 (39.1%) | – | – |
| Others | None | – | – |
| ALT (n,%) | |||
| > 40 (IU/L)b | 28 (43.7%) | 4 (8.9%) | 7 (25.0%) |
| ≤40 (IU/L)b | 36 (56.3%) | 41 (91.1%) | 21 (75.0%) |
| AST (n,%) | |||
| > 40 (IU/L)b | 30 (46.9%) | 1 (2.2%) | 7 (25.0%) |
| ≤40 (IU/L)b | 34 (53.1%) | 44 (97.8%) | 21 (75.0%) |
| CD4+ T cells/μLa | 882 (599–1088) | 888 (658–1119) | 445 (346–587) |
Data presented as amedians (inter-quartile range) or bnumber of cases (%)
BMI body mass index, ALT alanine aminotransferase, AST aspartate aminotransferase
Genotype and allele frequency distributions of IFNL3and RORCSNPs in the primary cohort
| SNP | Genotype | Chronic HCVa( | Resolved HCVa( | OR (95% CI) | |
|---|---|---|---|---|---|
| rs12979860 | CC | 55 (0.85) | 70(0.96) | 0.105 | |
| TT | 1 (0.02) | 0 (0.00) | |||
| CT | 8 (0.13) | 3 (0.04) | |||
| C allele | 118 (0.92) | 143 (0.98) |
| 0.25 (0.07–0.87) | |
| T allele | 10 (0.08) | 3 (0.02) | 4.04 (1.15–13.89) | ||
| rs8099917 | TT | 58(0.91) | 69 (0.95) | 0.514 | |
| GG | 0 (0.00) | 0 (0.00) | |||
| GT | 6 (0.09) | 4 (0.05) | |||
| T allele | 122 (0.95) | 142 (0.97) | 0.523 | 0.57 (0.16–2.08) | |
| G allele | 6 (0.05) | 4 (0.03) | 1.75 (0.48–6.33) | ||
| rs12980275 | AA | 55 (0.85) | 69 (0.96) | 0.189 | |
| GG | 1 (0.02) | 0 (0.00) | |||
| AG | 8 (0.13) | 4 (0.04) | |||
| A allele | 118 (0.92) | 142 (0.97) | 0.096 | 0.33 (0.10–1.09) | |
| G allele | 10 (0.08) | 4 (0.03) | 3.01 (0.92–9.84) | ||
| rs9826 | CC | 7 (0.11) | 1 (0.01) |
| |
| (3′ UTR) | TT | 29 (0.45) | 45 (0.62) | ||
| CT | 28 (0.44) | 27 (0.37) | |||
| C allele | 42 (0.33) | 29 (0.20) |
| 1.97 (1.14–3.41) | |
| T allele | 86 (0.67) | 117 (0.80) | 0.51 (0.29–0.88) | ||
| rs1521177 | GG | 6 (0.10) | 1 (0.01) |
| |
| (intron) | TT | 29 (0.45) | 48 (0.66) | ||
| GT | 29 (0.45) | 24 (0.33) | |||
| G allele | 41 (0.32) | 26 (0.18) |
| 2.18 (1.24–3.82) | |
| T allele | 87 (0.68) | 120 (0.82) | 0.46 (0.26–0.81) | ||
aNumber of cases (frequency). SNP genotypes were determined using the iPLEX MassARRAY system (Sequenom Inc., USA), and allele frequencies and genotype distributions were calculated. Chi-square (χ2) and Fisher’s exact tests were used to evaluate differences in SNP frequencies between HCV carriers and spontaneous resolvers. P-values, odds ratios, (ORs), and 95% confidence intervals, (95% CIs) were determined for association analysis. P-values (two-tailed) < 0.05 were considered significant (bold)
Genotype and allele distributions of SNPs in the RORC gene in the IFNL3 favorable sub-cohorta
| Chronic HCVb ( | Resolved HCVb ( | OR (95% CI) | ||
|---|---|---|---|---|
| rs9826 | ||||
| CC | 5 (0.09) | 1 (0.01) | 0.092 | |
| TT | 26 (0.48) | 41 (0.61) | ||
| CT | 23 (0.43) | 25 (0.37) | ||
| C allele | 33 (0.31) | 27 (0.20) | 0.062 | 1.74 (0.97–3.19) |
| T allele | 75 (0.69) | 107 (0.80) | 0.57 (0.31–1.03) | |
| rs1521177 | ||||
| GG | 6 (0.11) | 1 (0.01) |
| |
| TT | 26 (0.48) | 43 (0.64) | ||
| GT | 22 (0.41) | 23 (0.34) | ||
| G allele | 34 (0.31) | 25 (0.19) |
| 2.00 (1.11–3.55) |
| T allele | 74 (0.69) | 109 (0.81) | 0.50 (0.28–0.90) | |
aParticipants in the, IFNL3 favorable sub-cohort were screened for, IFNL3 genotypes (rs12979860CC/rs8099917TT/rs12980275AA)
bNumber of cases (frequency)
SNP genotyping was conducted using the iPLEX MassARRAY system (Sequenom Inc., USA), and allele and genotype frequency distributions were calculated. Chi-square (χ2) and Fisher’s exact tests were used to evaluate differences in, SNP frequencies between, HCV carriers and spontaneous resolvers. P-values, odds ratios, (ORs) and 95% confidence intervals, (95% CIs) were determined for association analysis. P-values (two-tailed) < 0.05were considered significant (bold)
Common RORC SNP haplotypes (rs9826/rs1521177) and their association with spontaneous viral clearance in the primary cohort and IFNL3 favorable sub-cohort
| Chronic HCVa | Resolved HCVa | OR (95% CI) | ||
|---|---|---|---|---|
| Primary cohort | ||||
| T/T | 0.62 | 0.79 |
| 0.445(0.26–0.76) |
| C/G | 0.27 | 0.16 |
| 1.893(1.05–3.40) |
| T/T | 0.64 | 0.78 |
| 0.485(0.28–0.86) |
| C/G | 0.26 | 0.17 | 0.1042 | 1.672(0.90–3.12) |
aHaplotype frequency. Chi-square (χ2) tests were used to evaluate differences in haplotype frequencies between, HCV carriers and spontaneous resolvers, using SHEsis software. Haplotypes with frequencies < 0.05 (C/T, C/G, C/T, T/G) are not shown. P-values, odds ratios, (ORs) and 95% confidence intervals (95% CIs) were determined for association analysis. P-values (two-tailed) < 0.05 were considered significant (bold)